US based Perspective Therapeutics reported a quarterly loss of $0.29 per share , wider than market expectations, reflecting continued investment in clinical development. Revenue estimates stood near $283.9 million , highlighting early stage commercial traction. Investors are closely tracking cash burn and trial progress as the company advances its targeted alpha therapy pipeline amid heightened scrutiny in biotech markets.